Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "Young Jin Choi"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
Epidemiology of Second Non-breast Primary Cancers among Survivors of Breast Cancer: A Korean Population–Based Study by the SMARTSHIP Group
Haeyoung Kim, Su SSan Kim, Ji Sung Lee, Jae Sun Yoon, Hyun Jo Youn, Hyukjai Shin, Jeong Eon Lee, Se Kyung Lee, Il Yong Chung, So-Youn Jung, Young Jin Choi, Jihyoung Cho, Sang Uk Woo, Korean Breast Cancer Society
Cancer Res Treat. 2023;55(2):580-591.   Published online December 27, 2022
DOI: https://doi.org/10.4143/crt.2022.410
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the incidence and prognosis of second non-breast primary cancer (SNBPC) among Korean survivors of breast cancer.
Materials and Methods
Data from the Korean National Health Insurance Service were searched to identify women who received curative surgery for initial breast cancer (IBC) between 2003 and 2008 (n=64,340). Among them, patients with the following characteristics were excluded: other cancer diagnosis before IBC (n=10,866), radiotherapy before IBC (n=349), absence of data on sex or age (n=371), or male (n=248). Accordingly, data of 52,506 women until December 2017 were analyzed. SNBPC was defined as a newly diagnosed SNBPC that occurred 5 years or more after IBC diagnosis.
Results
The median follow-up time of all patients was 12.13 years. SNBPC was developed in 3,084 (5.87%) women after a median of 7.61 years following IBC diagnosis. The 10-year incidence of SNBPC was 5.78% (95% confidence interval [CI], 5.56 to 6.00). Higher SNBPC incidence was found in survivors with the following factors: old age at IBC diagnosis, low household income, and receiving combined chemotherapy with endocrine therapy, whereas receiving radiotherapy was related to a lower incidence of SNBPC (hazard ratio, 0.89; p < 0.01). Among the patients with SNBPC, the 5-year survival rate was 62.28% (95% CI, 65.53 to 69.02).
Conclusion
Approximately 5% of breast cancer survivors developed SNBPC within 10 years after IBC diagnosis. The risk of SNBPC was associated with patient’s age at IBC diagnosis, income level, and a receipt of systemic treatments.

Citations

Citations to this article as recorded by  
  • Association of radiotherapy for stage I–III breast cancer survivors and second primary malignant cancers: a population-based study
    Jin Shi, Jian Liu, Guo Tian, Daojuan Li, Di Liang, Jun Wang, Yutong He
    European Journal of Cancer Prevention.2024; 33(2): 115.     CrossRef
  • 4,656 View
  • 91 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(4):1578-1588.   Published online April 16, 2019
DOI: https://doi.org/10.4143/crt.2018.671
AbstractAbstract PDFPubReaderePub
Purpose
Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC.
Materials and Methods
From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.
Results
Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]).
Conclusion
Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

Citations

Citations to this article as recorded by  
  • A perspective on the application of macrocyclic design strategies in antitumor drugs
    Yan-Hong Li, Yu-Kang Lin, Jian-Fan Cai, Zhong-Kai Zou, Pei-Liang Zhao
    Bioorganic Chemistry.2025; 156: 108190.     CrossRef
  • Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
    Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
    International Journal of Cancer.2024; 154(6): 947.     CrossRef
  • Cancer stem cells and angiogenesis
    Yanru Yang, Jingyu Guo, Mingyang Li, Guangxin Chu, Hai Jin, Jing Ma, Qingge Jia
    Pathology - Research and Practice.2024; 253: 155064.     CrossRef
  • Renal cancer: signaling pathways and advances in targeted therapies
    Aimin Jiang, Jinxin Li, Ziwei He, Ying Liu, Kun Qiao, Yu Fang, Le Qu, Peng Luo, Anqi Lin, Linhui Wang
    MedComm.2024;[Epub]     CrossRef
  • Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
    Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
    Jingyang Lin, Qingxia Fang, Xiaochun Zheng, Meng Li
    PLOS ONE.2023; 18(2): e0281402.     CrossRef
  • Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies
    Shawna R. Calhoun, Manish Sharma, Chung-Han Lee
    Kidney Cancer.2023; 7(1): 123.     CrossRef
  • 8,158 View
  • 184 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Analysis of the Prognostic Factors for Distant Metastasis after Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Head and Neck Cancer
Dong Hyun Kim, Won Taek Kim, Joo Hye Lee, Yong Kan Ki, Ji Ho Nam, Byung Joo Lee, Jin Choon Lee, Young Jin Choi, Young Mi Seol, Dong Won Kim
Cancer Res Treat. 2015;47(1):46-54.   Published online August 25, 2014
DOI: https://doi.org/10.4143/crt.2013.212
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study is to identify the prognostic factors of distant metastasis (DM) after induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer (HNC). Materials and Methods A total of 321 patients with HNC who underwent IC followed by CRT treated between January 2005 and December 2010 were analyzed retrospectively. IC consisted of three courses of docetaxel (70 mg/m2) and cisplatin (75 mg/m2) every three weeks, followed by radiotherapy of 66-70 Gy/2 Gy per fraction/5 fractions per week concurrent with weekly cisplatin (40 mg/m2). Tumor/nodal stage, primary site, tumor differentiation, lower neck node involvement (level IV, VB, and supraclavicular regions), number of concurrent chemotherapy cycles, overall duration of radiotherapy, and response to IC were assessed as potential prognostic factors influencing DM and survival outcome. Results The five-year loco-regional recurrence and DM rates were 23.6% and 18.2%. N stage, overall duration of radiotherapy, lower neck node involvement, and response to IC were significant factors for DM. With a median follow-up period of 52 months (range, 4 to 83 months), the 5-year progression-free, DM-free, and overall survival rates were 41.2%, 50.7%, and 55.1%, respectively. Lower neck node involvement (p=0.008) and poor response to IC (p < 0.001) showed an association with significantly inferior DM-free survival. Conclusion Even with the addition of IC, the DM rate and survival outcome were poor when metastatic lower neck lymph nodes were present or when patients failed to respond after receiving IC.

Citations

Citations to this article as recorded by  
  • Therapeutic Drug Monitoring of 5-Fluorouracil in Head and Neck Cancer Patients: An Interventional Pilot Study
    P. Sharmila Nirojini, N.K. Bhuvaneshwari, N. Dharsshini, S. Dhivya Bharathi, K. Velavan
    Indian Journal of Medical and Paediatric Oncology.2024; 45(02): 134.     CrossRef
  • An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375)
    Jinlong Wei, Jing Su, Jianfeng Wang, Xiaojing Jia, Qin Zhao, Weiyan Shi, Huanhuan Wang, Zhuangzhuang Zheng, Xin Jiang
    Head & Neck.2024; 46(4): 915.     CrossRef
  • Current status of systemic therapy in head and neck cancer
    Abhenil Mittal, Atul Sharma
    Journal of Chemotherapy.2022; 34(1): 9.     CrossRef
  • Risk stratification of postoperative recurrence in hypopharyngeal squamous-cell carcinoma patients with nodal metastasis
    Hanqing Lin, Tian Wang, Yu Heng, Xiaoke Zhu, Liang Zhou, Ming Zhang, Yong Shi, Pengyu Cao, Lei Tao
    Journal of Cancer Research and Clinical Oncology.2021; 147(3): 803.     CrossRef
  • Clinical characteristics of head and neck cancers at a tertiary care hospital
    Sajid Durrani, Saleh Al-Dhahari, Haneen Sebeih, Tariq Wani, Khalid Al Qahatani, Humariya Heena
    Population Medicine.2020;[Epub]     CrossRef
  • Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy
    Simon Keek, Sebastian Sanduleanu, Frederik Wesseling, Reinout de Roest, Michiel van den Brekel, Martijn van der Heijden, Conchita Vens, Calareso Giuseppina, Lisa Licitra, Kathrin Scheckenbach, Marije Vergeer, C. René Leemans, Ruud H Brakenhoff, Irene Naut
    PLOS ONE.2020; 15(5): e0232639.     CrossRef
  • Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience
    Or Dagan, Assaf Moore, Yuval Nachalon, Uri Alkan, Ameen Biadsee, Isaac Shochat, Aron Popovtzer
    Head & Neck.2020; 42(11): 3118.     CrossRef
  • Meta‐analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck
    Kimberley L. Kiong, Nurun Nisa de Souza, Rehena Sultana, N. Gopalakrishna Iyer
    The Laryngoscope.2018; 128(7): 1594.     CrossRef
  • Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
    R.I. Haddad, M. Posner, R. Hitt, E.E.W. Cohen, J. Schulten, J.-L. Lefebvre, J.B. Vermorken
    Annals of Oncology.2018; 29(5): 1130.     CrossRef
  • Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief
    Andy Karabajakian, Max Gau, Thibault Reverdy, Eve-Marie Neidhardt, Jérôme Fayette
    Cancers.2018; 11(1): 15.     CrossRef
  • Revisiting Induction Chemotherapy Before Radiotherapy for Head and Neck Cancer, Part I: Carcinoma of Non-Nasopharyngeal Sites
    Christopher H Chapman, Upendra Parvathaneni, Sue S Yom
    Future Oncology.2017; 13(6): 469.     CrossRef
  • Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer
    Mi Joo Chung, Yeon Sil Kim, Ji Yoon Kim, Yun Hee Lee, Ji Hyun Jang, Jin Hyoung Kang, Ie Ryung Yoo, Youn Soo Lee
    Cancer Research and Treatment.2016; 48(4): 1167.     CrossRef
  • The impact of treatment on quality of life of patients with head and neck cancer and its association with prognosis
    J.F. Carrillo, L.C. Carrillo, M.C. Ramirez-Ortega, F.J. Ochoa-Carrillo, L.F. Oñate-Ocaña
    European Journal of Surgical Oncology (EJSO).2016; 42(10): 1614.     CrossRef
  • Higher positive lymph node ratio indicates poorer distant metastasis–free survival in adenoid cystic carcinoma patients with nodal involvement
    Zhonglong Liu, Zao Fang, Tianguo Dai, Chenping Zhang, Jian Sun, Yue He
    Journal of Cranio-Maxillofacial Surgery.2015; 43(6): 751.     CrossRef
  • 13,142 View
  • 91 Download
  • 13 Web of Science
  • 14 Crossref
Close layer
Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
Seong Hoon Shin, Ho Sup Lee, Yang Soo Kim, Young Jin Choi, Sung Hyun Kim, Hyuk Chan Kwon, Sung Yong Oh, Jung Hun Kang, Chang Hak Sohn, Sang Min Lee, Jin Ho Baek, Young Joo Min, Choongrak Kim, Joo Seop Chung
Cancer Res Treat. 2014;46(4):331-338.   Published online July 21, 2014
DOI: https://doi.org/10.4143/crt.2013.130
AbstractAbstract PDFPubReaderePub
Purpose
To evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbance and relieving cancer pain. Materials and Methods One hundred twenty cancer patients with pain (numeric rating scale [NRS] ≥ 4) and sleep disturbance (NRS ≥ 4) were evaluated. The initial HM-OROS dosing was based on previous opioid dose (HM-OROS:oral morphine=1:5). Dose adjustment of the study drug was permitted at the investigator’s discretion. Pain intensity, number of breakthrough pain episodes, and quality of sleep were evaluated. Results A total of 120 patients received at least one dose of HM-OROS; 74 of them completed the final assessment. Compared to the previous opioids, HM-OROS reduced the average pain NRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), sleep disturbance NRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain at night from 2.63 to 1.53 times (p < 0.001), and immediate-release opioids use for the management of breakthrough pain from 0.83 to 0.39 times per night (p = 0.001). Of the 74 patients who completed the treatment, 83.7% indicated that they preferred HM-OROS to the previous medication. The adverse events (AEs) were somnolence, asthenia, constipation, dizziness, and nausea. Conclusion HM-OROS was efficacious in reducing cancer pain and associated sleep disturbances. The AEs were manageable.

Citations

Citations to this article as recorded by  
  • Pain and Analgesic Related Insomnia
    Jana Mlíchová, Zoltán Paluch, Ondřej Šimandl
    Pain Management Nursing.2023; 24(3): 254.     CrossRef
  • Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients
    Mi-Young Kwon, Ha-Na Cho, Dong-Hoe Koo, Yun-Gyoo Lee, Sukjoong Oh, Seung-Sei Lee
    The Korean Journal of Internal Medicine.2018; 33(3): 577.     CrossRef
  • Endogenous Opiates and Behavior: 2015
    Richard J. Bodnar
    Peptides.2017; 88: 126.     CrossRef
  • Drug Formulation Advances in Extended-Release Medications for Pain Control
    Mark R. Jones, Martin J. Carney, Rachel J. Kaye, Amit Prabhakar, Alan D. Kaye
    Current Pain and Headache Reports.2016;[Epub]     CrossRef
  • The Clinical Applications of Extended-Release Abuse-Deterrent Opioids
    Nalini Vadivelu, Erika Schermer, Gopal Kodumudi, Jack M. Berger
    CNS Drugs.2016; 30(7): 637.     CrossRef
  • Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
    Cheol Kyu Park, Hyun-Wook Kang, In-Jae Oh, Young-Chul Kim, Yeo-Kyeoung Kim, Kook-Joo Na, Sung-Ja Ahn, Tae Ok Kim, Young Jin Choi, Geun Am Song, Min Ki Lee
    Journal of Korean Medical Science.2016; 31(12): 1914.     CrossRef
  • 13,298 View
  • 81 Download
  • 6 Crossref
Close layer
Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
Dong Soo Lee, Jin Hyoung Kang, Chang Geol Lee, Seoung Jun Kim, Young Jin Choi, Kyo Young Lee, Yeon Sil Kim
Cancer Res Treat. 2013;45(2):95-102.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.95
AbstractAbstract PDFPubReaderePub
PURPOSE
A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC.
MATERIALS AND METHODS
Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR) mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone, pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain.
RESULTS
The median age of the cohort was 65 years (range, 31 to 88 years). The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%) patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006), whole-body metastatic score (p<0.001), and EGFR mutation status (p=0.095) were significantly or marginally associated with OS.
CONCLUSION
The results of the present study demonstrated that whole-body metastatic extent strongly affects survival outcome, even after adjustment for other significant variables in advanced non-squamous NSCLC. The clinical validity of more curative multimodal approaches in cohorts with limited metastases remains to be explored.

Citations

Citations to this article as recorded by  
  • Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
    Boyeon Kim, Young Soo Park, Jae Sook Sung, Jong Won Lee, Saet Byeol Lee, Yeul Hong Kim
    Cancer Medicine.2021; 10(1): 372.     CrossRef
  • Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents
    Cláudia Freitas, Maria Jacob, Nuno Tavares, Natália Cruz-Martins, Conceição Souto-Moura, David Araújo, Hélder Novais-Bastos, Vanessa Santos, Gabriela Fernandes, Adriana Magalhães, Venceslau Hespanhol, Henrique Queiroga
    Anti-Cancer Drugs.2021; 32(5): 567.     CrossRef
  • O impacto da histologia do carcinoma pulmonar na frequência das metástases ósseas
    Marcelo Bragança dos Reis Oliveira, Larissa Costa Souza, Ermides Javier Garcia Sampayo, Gustavo Sobral de Carvalho, Fernanda Carvalho de Queiroz Mello, Marcos Eduardo Machado Paschoal
    Revista Brasileira de Ortopedia.2019; 54(05): 524.     CrossRef
  • Brain Metastases at Presentation in Patients With Non–Small Cell Lung Cancer
    Saiama N. Waqar, Sadaf H. Waqar, Kathryn Trinkaus, Carlos A. Gadea, Cliff G. Robinson, Jeffrey Bradley, Mark A. Watson, Varun Puri, Ramaswamy Govindan, Daniel Morgensztern
    American Journal of Clinical Oncology.2018; 41(1): 36.     CrossRef
  • Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
    Lizet Sanchez, Leacky Muchene, Patricia Lorenzo-Luaces, Carmen Viada, Pedro C. Rodriguez, Sailyn Alfonso, Tania Crombet, Elia Neninger, Ziv Shkedy, Agustin Lage
    Seminars in Oncology.2018; 45(1-2): 52.     CrossRef
  • Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer
    Amanda Jane Williams Gibson, Haocheng Li, Adrijana D’Silva, Roxana A. Tudor, Anifat A. Elegbede, Shannon Mary Otsuka, D. Gwyn Bebb, Winson Y. Cheung
    Medical Oncology.2018;[Epub]     CrossRef
  • PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL
    Marcelo Bragança dos Reis Oliveira, Bruno de Carvalho Marques, Rosa Aurílio Matos, César Rubens da Costa Fontenelle, Fernanda Carvalho de Queiroz Mello, Marcos Eduardo Machado Paschoal
    Acta Ortopédica Brasileira.2018; 26(6): 388.     CrossRef
  • Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes
    Dong Soo Lee, Kyung Ran Park, Seung Joon Kim, Mi Joo Chung, Yun Hee Lee, Ji Hyun Chang, Jin Hyoung Kang, Sook Hee Hong, Myung Sin Kim, Yeon Sil Kim
    Tumor Biology.2016; 37(1): 619.     CrossRef
  • Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer
    Dong Soo Lee, Yeon S. Kim, Chul S. Kay, Sung H. Kim, Chang D. Yeo, Jin W. Kim, Seung Joon Kim, Young K. Kim, Yoon H. Ko, Jin H. Kang, Kyo Y. Lee
    Medicine.2016; 95(6): e2795.     CrossRef
  • Rare occurrence of cavitation of lung metastases following effective targeted therapy: A case report
    JIACHENG SONG, JING YU, ZHANLONG MA, SHANSHAN LU
    Oncology Letters.2016; 11(2): 1589.     CrossRef
  • Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology
    Hatice Odabas, Arife Ulas, Kubra Aydin, Mevlude Inanc, Asude Aksoy, Dogan Yazilitas, Mehmet Turkeli, Sinemis Yuksel, Ali Inal, Ahmet S. Ekinci, Alper Sevinc, Nebi S. Demirci, Mukremin Uysal, Necati Alkis, Faysal Dane, Mehmet Aliustaoglu, Mahmut Gumus
    Tumor Biology.2015; 36(12): 9641.     CrossRef
  • Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer
    Dong Soo Lee, Seung Joon Kim, Hong Seok Jang, Ie Ryung Yoo, Kyung Ran Park, Sae Jung Na, Kyo Young Lee, Sook Hee Hong, Jin Hyoung Kang, Young Kyoon Kim, Yeon Sil Kim
    Medicine.2015; 94(32): e1304.     CrossRef
  • A case of lung cancer complicated by axillary Castleman's disease
    Manabu Kakizoe, Kousuke Suzuki, Noriyuki Saeki
    The Journal of the Japanese Association for Chest Surgery.2015; 29(6): 722.     CrossRef
  • Non-small cell lung cancer metastasis to the oral cavity: a case report
    JB Olsen, F Sim, A Chandu
    Australian Dental Journal.2014; 59(4): 520.     CrossRef
  • Lung Cancer Coexisting With Ipsilateral Pleural Effusion
    Francisco Rodriguez-Panadero, Beatriz Romero-Romero
    Lung Cancer Management.2014; 3(4): 335.     CrossRef
  • EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
    Ukhyun Jo, Kyong Hwa Park, Young Mi Whang, Jae Sook Sung, Nam Hee Won, Jong Kuk Park, Yeul Hong Kim
    Oncotarget.2014; 5(5): 1265.     CrossRef
  • 11,490 View
  • 76 Download
  • 16 Crossref
Close layer
Docetaxel and Cisplatin Combination Chemotherapy in Patients with Squamous Cell Carcinomas of the Head and Neck
Jung Hyun Lee, Kyung Woo Lee, Young Jin Choi, Jae Hoon Choi, Ho Jin Shin, Joo Seop Chung, Goon Jae Cho, Byung Ju Lee, Soo Geun Wang
Cancer Res Treat. 2003;35(3):261-266.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.261
AbstractAbstract PDF
PURPOSE
The objective of this phase II study was to assess the clinical antitumor activity and toxicities of docetaxel and cisplatin chemotherapy, in patients with locally advanced and metastatic, recurrent squamous cell carcinomas of the head and neck (SCCHN). MATERIALS AND METHODS: All eligible patients with locally advanced and metastatic, recurrent SCCHN had received two courses of chemotherapy followed by repeated head and neck examinations and computed tomography. Patients who had received prior chemotherapy with taxanes were ineligible. If the patients achieved a response (either CR or PR), they received one more course of chemotherapy prior to undergoing definitive local treatment. The combination chemotherapy consisted of docetaxel, 70 mg/m2, and cisplatin, 75 mg/m2, on day 1, with the cycles repeated every 3~4 weeks. RESULTS: All 32 patients were assessable for response and toxicity analyses. The most common grade 3/4 adverse event was neutropenia, which occurred in 11% of cases. No febrile neutropenia was noticed. The other grade 3/4 adverse events included: anemia (2%) and stomatitis (3%). The response rate in patients with locally advanced cancer was 19/21 (90%). Fifteen patients (71%) achieved a CR and 4 (19%) a PR. Out of the 4 patients presenting with a distant metastatic disease, 1 each achieved CR and PR, with 2 stable disease (SD). Out of the 7 patients with a recurrence at a distant site, 1 each achieved PR and SD, and 5 (71%) had a progression of the disease (PD). The overall response rate was 22/32 (69%).
CONCLUSION
Docetaxel plus cisplatin is an effective regimen with an acceptable toxicity profile. This regimen may offer high antitumor activity on short outpatient administration, with a low incidence of severe toxicity.

Citations

Citations to this article as recorded by  
  • The Analysis of Induction Chemotherapy Using Docetaxel and Platinum in Treatment of Hypopharyngeal Carcinoma
    Jongseung Kim, Kyengsuk Lee, Byungeon Hwang, Sangho Lim, Sunho Ryu, Ilwoo Ha, Eun Jung Lee, Kihwan Hong, Yunsu Yang
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2010; 53(11): 706.     CrossRef
  • The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer
    Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim, Joon-Kyoo Lee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Chul Lim, Hyeoung-Joon Kim, Woong-Ki Chung, Ik-Joo Chung
    Cancer Research and Treatment.2007; 39(3): 93.     CrossRef
  • 5,106 View
  • 21 Download
  • 2 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP